CJ
Juillard Mochon, Catherine
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Association between SARS-CoV-2 infection and anti-apolipoprotein A-1 antibody in children | Frontiers in immunology |  | 2025 | 52 | 67 | ||
| Anti-Apolipoprotein A-1 IgG, incident cardiovascular events and lipid paradox inrheumatoid arthritis | ESC (Europan Society of Cardiology) Congress 2024 | 2024 | 4 | 0 | |||
| Anti-apolipoprotein A-1 IgG, incident cardiovascular events and lipid paradox in rheumatoid arthritis | 92nd EAS (European Atherosclerosis Society) Congress | 2024 | 7 | 0 | |||
| Anti-apolipoprotein A-1 IgG, incident cardiovascular events, and lipid paradox in rheumatoid arthritis | Frontiers in cardiovascular medicine | | 2024 | 114 | 149 | ||
| Linking antibody against apolipoprotein A-1 to nonalcoholic steatohepatitis in mice | 92nd EAS (European Atherosclerosis Society) Congress | 2024 | 5 | 0 | |||
| Linking antibody against apolipoprotein A-1 to metabolic dysfunction-associatedsteatohepatitis in mice | ESC (Europan Society of Cardiology) Congress 2024 | 2024 | 3 | 0 | |||
| Linking Antibodies Against Apolipoprotein A-1 to Metabolic Dysfunction-Associated Steatohepatitis in Mice | International journal of molecular sciences | | 2024 | 120 | 112 | ||
| Antibody against apolipoprotein-A1, Metabolic-Associated Fatty Liver Diseaseand cardiovascular risk : a translational study | ESC (European Society of Cardiology) Congress 2023 | 2023 | 3 | 0 | |||
| Antibody against apolipoprotein-A1, non-alcoholic fatty liver disease and cardiovascular risk: a translational study | Journal of translational medicine | | 2023 | 139 | 117 | ||
| Impact of SARS-CoV2 infection on anti-apolipoprotein A-1 IgG response in inflammatory rheumatic diseases | Frontiers in immunology | | 2023 | 130 | 81 | ||
| Serum Level of Cytokeratin 18 (M65) as a Prognostic Marker of High Cardiovascular Disease Risk in Individuals with Non-Alcoholic Fatty Liver Disease | Biomolecules | | 2023 | 75 | 133 | ||
| High antibody titers against apolipoprotein-A1 in NAFLD: a possible link between fatty liver disease and CVD? | 90th European Atherosclerosis Society (EAS) congress | 2022 | 156 | 0 | |||
| SARS-COV2- infection as a trigger of humoral response against apolipoprotein A-1 | EAS Congress 2021 | 2021 | 382 | 38 | |||
| SARS-CoV-2 infection as a trigger of humoral response against apolipoprotein A-1 | European Journal of Clinical Investigation | | 2021 | 418 | 256 | ||
| Autoantibodies directed against apolipoprotein-A1 as a potential contributor to Non-Alcoholic Fatty Liver Disease | 89th Europen Society of Atherosclerosis (EAS) | 2021 | 141 | 0 | |||
| Auto-antibodies against apolipoprotein a-1 block cancer cells proliferation and induce apoptosis | Oncotarget | | 2020 | 171 | 121 | ||
| Activation of human B cells negatively regulates TGF-β1 production | Journal of Neuroinflammation | | 2017 | 589 | 270 | ||
| The neurotrophic hepatocyte growth factor induces protolerogenic human dendritic cells | Journal of neuroimmunology |  | 2014 | 546 | 0 | ||
| Interferon-β induces hepatocyte growth factor in monocytes of multiple sclerosis patients | PloS one | | 2012 | 687 | 264 |
